^
Association details:
| Biomarker: | EGFR mutation + BRAF mutation + TP53 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
P89.15 - Multiple Driver Oncogenes from Plasma of NSCLC Patients
Published date:
01/12/2021
Excerpt:
A 52 yo gentlement was diagnosed as lung adenocarcinoma T4N3M1 stage IV on March 2016. While waiting for EGFR mutation, he was having 2 cycle of chemotherapy of cisplatin-pemetrexed-bevacizumab...On March 2019 he showed PD, and his plasma NGS on March 2019 showed EGFR del 19, EGFR T790M, BRAF V600E, TP53 R273H, TP53 Y220C.
Secondary therapy:
carboplatin + pemetrexed
